Start a ProjectMICRONEEDLE APPLICATION
Initial inputs include molecular properties, biological-activity methods, target dose, available stability data, formulation constraints and intended release profile. Development must manage moisture, temperature, interfacial and process stresses without assuming activity retention.
Evaluation may cover content and activity, matrix or coating compatibility, loading distribution, insertion, release, residual moisture, storage sensitivity and process-related variability. Methods and acceptance criteria are defined for the project stage.
Dissolving matrices may suit incorporated payloads; coated structures may suit lower-dose surface loading. Layered or microparticle-containing concepts can be assessed where localization or sustained release is relevant, subject to dose and manufacturability.
Stage outputs can include an input review, feasibility findings, candidate formulation and structure, prototype data, analytical observations, a risk register and a recommendation for the next development stage.
CASMN team research on gel-encapsulated coated microneedles provides a biopharmaceutical delivery example. It is scientific context and does not establish activity retention, approval or performance for a new peptide or protein program.
Feasibility and performance are project-specific and depend on payload properties, target dose, product design, analytical strategy and intended use. Technical Review — Reviewed by: CASMN R&D Team · Last reviewed: August 2026.
The team reviews payload properties, target dose, stability, intended use, delivery requirements and manufacturing constraints.
Technology selection is made project by project after reviewing dose, release profile, product use and process requirements.
No. Publications provide scientific context and do not establish regulatory approval, clinical performance or commercial availability.
Send your target product, payload, development stage and cooperation scope to our business development team.
Start a Project